McKesson assumed with a Neutral at Mizuho

Mizuho assumed coverage of McKesson (MCK) with a Neutral rating and $630 price target The stock’s investment story has morphed well beyond just a plain vanilla drug distribution story, as management has now put together a high-value $35B oncology platform that should allow for great-than-average visibility on the company’s ability to generate 12%-14% EPS CAGR over the next 3-5 years, the analyst tells investors in a research note. McKesson’s near-term upside may be limited however as shares have rallied about 30% over the past few months, the firm adds.